The patent covers optimization methods and systems relating to mathematical models of angiogenesis, which include pro-angiogenesis and anti-angiogenesis components – the regulatory factors; vascular endothelial growth factor, platelet derived growth factor, angiopoietin 1 and angiopoietin 2, etc.
Optimata’s technology also incorporates simulation of the process of vessel maturation and related development processes; as well as the effects of a drug or a combination of drugs on each of the model components and on the outcomes for disease progression.
Zvia Agur, founder and CSO of Optimata, said: “This patent reinforces Optimata’s leadership position in the field of predictive oncology. By using the analytical power of the Optimata Virtual Patient engine drug developers will obtain early indications about the angiogenic effects of drugs in development.”